

13. Jorga, K.; Fotteler, B.; Heizmann, P.; Gasser, R. Metabolism and Excretion of Tolcapone, a Novel Inhibitor of Catechol-O-methyltransferase. *Br. J. Clin. Pharmacol.* **1999**, *48*, 513–520.
14. a. Kang, P.; Dalvie, D.; Smith, E.; Renner, M. Bioactivation of Lumiracoxib by Peroxidases and Human Liver Microsomes: Identification of Multiple Quinone Imine Intermediates and GSH Adducts. *Chem. Res. Toxicol.* **2009**, *22*, 106–117.
b. Li, Y.; Slatter, G.; Zhang, Z.; Li, Y.; Doss, G. A.; Braun, M. P.; Stearns, R. A.; Dean, D. C.; Baillie, T. A.; Tang, W. *In Vitro* Metabolic Activation of Lumiracoxib in Rat and Human Liver Preparations. *Drug Metab. Dispos.* **2008**, *36*, 469–473.
15. a. Durand, A.; Thenot, J. P.; Bianchetti, G.; Morselli, P. L. Comparative Pharmacokinetic Profile of Two Imidazopyridine Drugs: Zolpidem and Alpidem. *Drug Metab. Rev.* **1992**, *24*, 239–266.
b. Usui, T.; Mise, M.; Hashizume, T.; Yabuki, M.; Komuro, S. Evaluation of the Potential for Drug-Induced Liver Injury Based on *In Vitro* Covalent Binding to Human Liver Proteins. *Drug Metab. Dispos.* **2009**, *37*, 2383–2392.
16. Kassahun, K.; Pearson, P. G.; Tang, W.; McIntosh, I.; Leung, K.; Elmore, C.; Dean, D.; Wang, R.; Doss, G.; Baillie, T. A. Studies on the Metabolism of Troglitazone to Reactive Intermediates *In Vitro* and *In Vivo*. Evidence for Novel Biotransformation Pathways Involving Quinone Methide Formation and Thiazolidinedione Ring Scission. *Chem. Res. Toxicol.* **2001**, *14*, 62–70.
17. Walsh, J. S.; Reese, M. J.; Thurmond, L. M. The Metabolic Activation of Abacavir by Human Liver Cytosol and Expressed Human Alcohol Dehydrogenase Isozymes. *Chem. Biol. Interact.* **2002**, *142*, 135–154.
18. a. Stepan, A. F.; Walker, D. P.; Bauman, J.; Price, D. A.; Baillie, T. A.; Kalgutkar, A. S.; Aleo, M. D. Structural Alert/Reactive Metabolite Concept as Applied in Medicinal Chemistry to Mitigate the Risk of Idiosyncratic Drug Toxicity: A Perspective Based on the Critical Examination of Trends in the Top 200 Drugs Marketed in the United States. *Chem. Res. Toxicol.* **2011**, *24*, 1345–1410.
b. Park, B. K.; Laverty, H.; Srivastava, A.; Antoine, D. J.; Naisbitt, D.; Williams, D. P. Drug Bioactivation and Protein Adduct Formation in the Pathogenesis of Drug-Induced Toxicity. *Chem. Biol. Interact.* **2011**, *192*, 30–36.
c. Kalgutkar, A. S.; Gardner, I.; Obach, R. S.; Shaffer, C. L.; Callegari, E.; Henne, K. R.; Mutlib, A. E.; Dalvie, D. K.; Lee, J. S.; Nakai, Y.; et al. A Comprehensive Listing of Bioactivation Pathways of Organic Functional Groups. *Curr. Drug Metab.* **2005**, *6*, 161–225.
d. Kalgutkar, A. S.; Didiuk, M. T. Structural Alerts, Reactive Metabolites, and Protein Covalent Binding: How Reliable Are These Attributes as Predictors of Drug Toxicity? *Chem. Biodivers.* **2009**, *6* (11), 2115–2137.
19. Soignet, S. L.; Frankel, S. R.; Douer, D.; Tallman, M. S.; Kantarjian, H.; Calleja, E.; Stone, R. M.; Kalaycio, M.; Scheinberg, D. A.; et al. United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia. *J. Clin. Oncol.* **2001**, *19* (18), 3852–3860.
20. a. Mosmann, T. Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays. *J. Immunol. Methods* **1983**, *65* (1–2), 55–63.
b. Berridge, M. V.; Herst, P. M.; Tan, A. S. Tetrazolium Dyes as Tools in Cell Biology: New Insights into Their Cellular Reduction. *Biotechnol. Annu. Rev.* **2005**, *11*, 127–152.
21. Decker, T.; Lohmann-Matthes, M. L. A Quick and Simple Method for the Quantitation of Lactate Dehydrogenase Release in Measurements of Cellular Cytotoxicity and Tumor Necrosis Factor (TNF) Activity. *J. Immunol. Methods* **1998**, *115* (1), 61–69.
22. Repetto, G.; del Peso, A.; Zurita, J. L. Neutral Red Uptake Assay for the Estimation of Cell Viability/Cytotoxicity. *Nat. Protoc.* **2008**, *3* (7), 1125–1131.
23. Dorland. *Dorland's Medical Dictionary: Dorland's Illustrated Medical Dictionary* (32nd ed.). Elsevier Health Sciences; 2011.